{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T07:47:26Z","timestamp":1794210446131,"version":"4.8.0"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1097\/gme.0b013e318279ba64","type":"journal-article","created":{"date-parts":[[2013,1,29]],"date-time":"2013-01-29T16:29:08Z","timestamp":1359476948000},"page":"623-630","source":"Crossref","is-referenced-by-count":212,"title":["Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy"],"prefix":"10.1097","volume":"20","author":[{"given":"David J.","family":"Portman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria A.","family":"Bachmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20210211","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4065\/mcp.2009.0413","article-title":"Vulvovaginal atrophy.","volume":"85","author":"Mac Bride","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"R2-7-20210211","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/13697130802585576","article-title":"Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overview.","volume":"12","author":"Al-Baghdadi","year":"2009","journal-title":"Climacteric"},{"key":"R3-7-20210211","first-page":"S14","article-title":"Impact of vaginal atrophy on quality of life and sexuality.","volume":"22","author":"Krychman","year":"2010","journal-title":"OBG Manag"},{"key":"R6-7-20210211","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1089\/jwh.2009.1384","article-title":"Recognizing and treating urogenital atrophy in postmenopausal women.","volume":"19","author":"Goldstein","year":"2010","journal-title":"J Womens Health"},{"key":"R7-7-20210211","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1111\/j.1743-6109.2009.01335.x","article-title":"Prevalence and impact of vaginal symptoms among postmenopausal women.","volume":"6","author":"Santoro","year":"2009","journal-title":"J Sex Med"},{"key":"R8-7-20210211","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1080\/13697130902814751","article-title":"Urogenital atrophy.","volume":"12","author":"Calleja-Agius","year":"2009","journal-title":"Climacteric"},{"key":"R9-7-20210211","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/j.1743-6109.2008.01198.x","article-title":"The use of estrogen therapy in womens sexual functioning (CME).","volume":"6","author":"Nappi","year":"2009","journal-title":"J Sex Med"},{"key":"R10-7-20210211","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/gme.0b013e3181c1ac01","article-title":"Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study.","volume":"17","author":"Bachmann","year":"2010","journal-title":"Menopause"},{"key":"R11-7-20210211","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/clpt.2010.161","article-title":"Progress and prospects in treating postmenopausal vaginal atrophy.","volume":"89","author":"Winneker","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"R12-7-20210211","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Womens Health Initiative randomized controlled trial.","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"key":"R13-7-20210211","first-page":"1233","article-title":"Predictors of difficulty when discontinuing postmenopausal hormone therapy.","volume":"102","author":"Grady","year":"2003","journal-title":"Obstet Gynecol"},{"key":"R14-7-20210211","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/gme.0b013e31824b970a","article-title":"The 2012 hormone therapy position statement of: The North American Menopause Society.","volume":"19","year":"2012","journal-title":"Menopause"},{"key":"R15-7-20210211","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1097\/gme.0b013e3181c4f1d6","article-title":"Endometrial safety: a key hurdle for selective estrogen receptor modulators in development.","volume":"17","author":"Pinkerton","year":"2010","journal-title":"Menopause"},{"key":"R16-7-20210211","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1111\/j.1743-6109.2009.01692.x","article-title":"Vulvovaginal atrophy: current and future therapies (CME).","volume":"7","author":"Ibe","year":"2010","journal-title":"J Sex Med"},{"issue":"Suppl 1","key":"R17-7-20210211","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/j.maturitas.2004.03.006","article-title":"The molecular determinants of estrogen receptor pharmacology.","volume":"48","author":"McDonnell","year":"2004","journal-title":"Maturitas"},{"key":"R21-7-20210211","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0378-5122(02)00206-2","article-title":"Effects of ospemifene (FC-1271a) on uterine endometrium, vaginal maturation index, and hormonal status in healthy postmenopausal women.","volume":"43","author":"Voipio","year":"2002","journal-title":"Maturitas"},{"key":"R22-7-20210211","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1742-7843.2008.00235.x","article-title":"Pharmacologic effects of ospemifene in rhesus macaques: a pilot study.","volume":"102","author":"Wurz","year":"2008","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"R23-7-20210211","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1210\/endo.141.2.7342","article-title":"Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats.","volume":"141","author":"Qu","year":"2000","journal-title":"Endocrinology"},{"key":"R24-7-20210211","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/00042192-200512020-00015","article-title":"Effects of ospemifene and raloxifene on hormonal status, lipids, genital tract, and tolerability in postmenopausal women.","volume":"12","author":"Komi","year":"2005","journal-title":"Menopause"},{"key":"R25-7-20210211","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/01.GME.0000063609.62485.27","article-title":"Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial.","volume":"10","author":"Rutanen","year":"2003","journal-title":"Menopause"},{"key":"R26-7-20210211","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.amjmed.2011.07.036","article-title":"Sexual activity and satisfaction in healthy community-dwelling older women.","volume":"125","author":"Trompeter","year":"2012","journal-title":"Am J Med"}],"container-title":["Menopause"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/gme.0b013e318279ba64","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T07:36:34Z","timestamp":1620977794000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00042192-201306000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/gme.0b013e318279ba64","relation":{},"ISSN":["1072-3714"],"issn-type":[{"value":"1072-3714","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]}}}